journal article·2025-02-26

Nanomedicine–lipoprotein interactions

S. Moein Moghimi, Dmitri Simberg

Nature Reviews Bioengineering· Volume 3· Issue 6
Publisher page

Abstract

No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.

Source: Not provided · Quality: missing

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Lipoproteins and Cardiovascular Health · Vitamin D Research Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (15)

Show source-provided references
1. Shah, A. S., Tan, L., Long, J. L. & Davidson, W. S. Proteomic diversity of high-density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J. Lipid Res. 54, 2575–2585 (2013).10.1194/jlr.R035725 ↗
2. Dilliard, S. A. & Siegwart, D. J. Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs. Nat. Rev. Mater. 8, 282–300 (2023).10.1038/s41578-022-00529-7 ↗
3. Williams, K. J., Phillips, M. C. & Rodrigueza, W. V Structural and metabolic consequences of liposome-lipoprotein interactions. Adv. Drug Deliv. Rev. 32, 31–43 (1998).10.1016/S0169-409X(97)00130-0 ↗
4. Courtney, H. S., Zhang, Y.-M., Frank, M. W. & Rock, C. O. Serum opacity factor, a streptococcal virulence factor that bind to apolipoproteins A-I and A-II and disrupts high density lipoprotein structure. J. Biol. Chem. 281, 5515–5521 (2006).10.1074/jbc.M512538200 ↗
5. Woodburn, K. & Kessel, D. The alteration of plasma lipoproteins by Cremophor EL. J. Photochem. Photobiol. 22, 197–201 (1994).10.1016/1011-1344(93)06968-9 ↗
6. Hamad, I., Hunter, A. C. & Moghimi, S. M. Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. J. Control. Release 170, 167–174 (2013).10.1016/j.jconrel.2013.05.030 ↗
7. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149–1157 (2007).10.1038/nbt1339 ↗
8. Sobot, D. et al. Circulating lipoproteins: A Trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells. Mol. Ther. 25, 1596–1605 (2017).10.1016/j.ymthe.2017.05.016 ↗
9. Michell, D. L. et al. Elucidation of physico-chemical principles of high-density lipoprotein-small RNA binding interactions. J. Biol. Chem. 298, 101952 (2022).10.1016/j.jbc.2022.101952 ↗
10. Guevara, J. G. Jr., Kang, D. & Moore, J. P. Nucleic acid-binding properties of low-density lipoproteins: LDL as a natural gene vector. J. Protein Chem. 18, 845–857 (1999).10.1023/A:1020627212272 ↗
11. Engelen, S. E. et al. Lipoproteins act as vehicles for lipid antigen delivery and activation of invariant natural killer T cells. JCI Insight 8, 158089 (2023).10.1172/jci.insight.158089 ↗
12. Szebeni, J. et al. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity. Int. Immunopharmacol. 1, 721–735 (2001).10.1016/S1567-5769(01)00006-6 ↗
13. Wasan, K. M. et al. Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J. Pharm. Pharmaceut. Sci. 6, 189–197 (2003).
14. Rosenson, R. S. et al. Dysfunctional and atherosclerotic cardiovascular disease. Nat. Rev. Cardiol. 13, 48–60 (2016).10.1038/nrcardio.2015.124 ↗
15. Kudinov, V. A. et al. High-density lipoprotein remodeling by phospholipid nanoparticles improves cholesterol efflux capacity and protects from atherosclerosis. Biomed. Pharmacother. 141, 111900 (2021).10.1016/j.biopha.2021.111900 ↗